JBM (Healthcare) Limited (2161.HK)
HKD 2.0
(-3.38%)
HKD 2.0
(-3.38%)
| Year | Total Debt | Total Debt Growth |
|---|---|---|
| 2023 | 133.4 Million HKD | -25.92% |
| 2022 | 180.09 Million HKD | -15.48% |
| 2021 | 213.09 Million HKD | -20.46% |
| 2020 | 267.91 Million HKD | -42.55% |
| 2019 | 466.36 Million HKD | -27.82% |
| 2018 | 646.12 Million HKD | -3.71% |
| 2017 | 671.01 Million HKD | 0.0% |
| Year | Total Debt | Total Debt Growth |
|---|---|---|
| 2023 FY | 133.4 Million HKD | -25.92% |
| 2023 Q2 | 144.73 Million HKD | 0.0% |
| 2023 Q4 | 133.4 Million HKD | 0.0% |
| 2022 Q4 | 180.09 Million HKD | 0.0% |
| 2022 FY | 180.09 Million HKD | -15.48% |
| 2022 Q2 | 189.48 Million HKD | 0.0% |
| 2021 Q2 | 246.97 Million HKD | 0.0% |
| 2021 FY | 213.09 Million HKD | -20.46% |
| 2021 Q4 | 213.09 Million HKD | 0.0% |
| 2020 Q2 | - HKD | -100.0% |
| 2020 Q4 | 267.91 Million HKD | 0.0% |
| 2020 Q1 | 389.35 Million HKD | 0.0% |
| 2020 FY | 267.91 Million HKD | -42.55% |
| 2019 FY | 466.36 Million HKD | -27.82% |
| 2018 FY | 646.12 Million HKD | -3.71% |
| 2017 FY | 671.01 Million HKD | 0.0% |
| Name | Total Debt | Total Debt Difference |
|---|---|---|
| Pak Fah Yeow International Limited | 6.8 Million HKD | -1858.987% |
| Grand Pharmaceutical Group Limited | 3.4 Billion HKD | 96.081% |
| Extrawell Pharmaceutical Holdings Limited | 120.41 Million HKD | -10.794% |
| Wai Yuen Tong Medicine Holdings Limited | 460.94 Million HKD | 71.058% |
| Qianhai Health Holdings Limited | 487 Thousand HKD | -27293.634% |
| Lee's Pharmaceutical Holdings Limited | 204.14 Million HKD | 34.649% |
| Essex Bio-Technology Limited | 294.02 Million HKD | 54.627% |
| Tongfang Kontafarma Holdings Limited | 333.82 Million HKD | 60.037% |
| PuraPharm Corporation Limited | 424.77 Million HKD | 68.593% |
| SSY Group Limited | 3.37 Billion HKD | 96.046% |
| Jacobson Pharma Corporation Limited | 749.37 Million HKD | 82.198% |
| China Resources Pharmaceutical Group Limited | 85.84 Billion HKD | 99.845% |